http://researchonline.federation.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:14837 Wed 25 Nov 2020 10:04:34 AEDT ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:14048 Wed 07 Apr 2021 14:02:08 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:13780 0.1). The depressor response to pentolinium was greater in BPH/2J than BPN/3J, but in both cases the response in RD mice was similar to sham. Enalaprilat decreased MAP more in RD BPH/2J compared to sham (−12 vs −3 mmHg, P < 0.001) but had no effect in BPN/3J. RD reduced renal noradrenaline in both strains but more so in BPH/2J. RD reduced renin mRNA and protein, but not plasma renin in BPH/2J to levels comparable with BPN/3J mice. We conclude that renal nerves contribute to hypertension in BPH mice as RD induced a sustained fall in MAP, which was associated with a reduction of intrarenal renin expression. The lack of inhibition of the depressor effects of pentolinium and enalaprilat by RD suggests that vasoconstrictor effects of the SNS or RAS are not involved.]]> Wed 07 Apr 2021 14:01:53 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:13680 Wed 07 Apr 2021 14:01:47 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:12775 Wed 07 Apr 2021 14:00:59 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:11958 Wed 07 Apr 2021 13:57:15 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:11640 Wed 07 Apr 2021 13:56:56 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:11392 Wed 07 Apr 2021 13:56:42 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:10751 Wed 07 Apr 2021 13:56:06 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:10738 Wed 07 Apr 2021 13:56:05 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:10341 Wed 07 Apr 2021 13:55:41 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:9603 1000 young apparently healthy white men from the general population. Each Y chromosome was classified into one of 13 most common European lineages. Androgens (DHEA-S, androstenedione, total testosterone) and their metabolites (total estradiol, estrone) were measured by radioimmunoassays. Information on five dimensions of aggression (total, physical, verbal, anger and hostility) was collected using Buss and Perry questionnaire. Results: Approximately 17% men inherited haplogroup I from their fathers. Carriers of haplogroup I showed lower scores of verbal aggression than men with other haplogroups (beta = -0.72, SE = 0.29, P = 0.012) and when further compared to carriers of most common R1a lineage and other haplogroups (beta = -1.03, SE = 0.34, P = 0.003). However, these associations did not survive a correction for multiple testing. Sex steroids did not show even nominal level of association with haplogroup I. Conclusion: Our data show no overall association between haplogroup I and sex-related phenotypes in young white men. These results also suggest that the previously identified association between haplogroup I and coronary artery disease is not likely mediated by unfavourable profile of sex steroids or heightened aggression early in life. (C) 2014 Elsevier Ireland Ltd. All rights reserved.]]> Wed 07 Apr 2021 13:54:51 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:7167 Wed 07 Apr 2021 13:46:40 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:7161 Wed 07 Apr 2021 13:46:39 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:6926 Wed 07 Apr 2021 13:46:28 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:5401 Wed 07 Apr 2021 13:45:02 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:5261 Wed 07 Apr 2021 13:44:54 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:5099 Wed 07 Apr 2021 13:44:43 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:4790 1.1) were differentially expressed between HHR and NHR (n=16). We then performed an in silico analysis to predict the miRNAs that are able to bind to the 3′ untranslated region of Endog mRNA, and therefore could regulate Endog levels. We discovered that the miRNAs let-7b, miR-338 and miR-347 are predicted to bind to Endog mRNA. Functional studies are being undertaken to determine whether these miRNAs can regulate Endog mRNA levels in vitro and their role in the pathological processes leading to cardiac hypertrophy. These miRNAs could be a new target for the prevention and treatment of cardiac hypertrophy in humans]]> Wed 07 Apr 2021 13:44:20 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:14703 = 18 years) recruited through opportunistic sampling were screened at sites in 92 countries during May 2019. Ideally, 3 blood pressure readings were measured for each participant, and data on lifestyle factors and comorbidities were collected. Hypertension was defined as a systolic blood pressure >= 140 mm Hg, or a diastolic blood pressure >= 90 mm Hg (mean of the second and third readings) or taking antihypertensive medication. When necessary, multiple imputation was used to estimate participants' mean blood pressure. Mixed-effects models were used to evaluate associations between blood pressure and participant characteristics. Of 1 508 130 screenees 482 273 (32.0%) had never had a blood pressure measurement before and 513 337 (34.0%) had hypertension, of whom 58.7% were aware, and 54.7% were on antihypertensive medication. Of those on medication, 57.8% were controlled to <140/90 mm Hg, and 28.9% to <130/80 mm Hg. Of all those with hypertension, 31.7% were controlled to <140/90 mm Hg, and 350 825 (23.3%) participants had untreated or inadequately treated hypertension. Of those taking antihypertensive medication, half were taking only a single drug, and 25% reported using aspirin inappropriately. This survey is the largest ever synchronized and standardized contemporary compilation of global blood pressure data. This campaign is needed as a temporary substitute for systematic blood pressure screening in many countries worldwide.]]> Tue 19 Oct 2021 16:23:32 AEDT ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:14247 Thu 20 May 2021 10:20:30 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:14223 Thu 19 May 2022 12:38:25 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:15013 Mon 12 Apr 2021 15:22:09 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:15692 80% had dyslipidaemia and <15% of patients were diagnosed with diabetes (DM). All of these disorders were more frequent in men. In 80% of patients the waist circumference exceed norm for the European population. Less than half of the patients were current smokers or had smoked in the past. Patients with CVD had significantly higher blood pressure and glucose levels but lower low density lipoprotein-cholesterol level. Conclusions: The prevalence of CVD and CV risk factors among patients in Poland is high. CVD is more common in men than in women. The most common CV risk factors are excess waist circumference, dyslipidaemia and HTN. Family physicians should conduct activities to prevent, diagnose early and treat CVD in the primary health care population. © 2021 Elsevier B.V. **Please note that there are multiple authors for this article therefore only the name of the first 5 including Federation University Australia affiliate “Fadi Charchar” is provided in this record**]]> Mon 07 Feb 2022 15:14:21 AEDT ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:5174 Fri 30 Apr 2021 15:48:56 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:15713 Fri 03 Nov 2023 12:12:48 AEDT ]]>